NCT02139072|Completed
CoaguChek XS in Antiphospholipid Antibody Syndrome (APL) Patients
Accuracy of CoaguChek XS in Patients With Antiphospholipid Antibody Syndrome
Loading search results
Accuracy of CoaguChek XS in Patients With Antiphospholipid Antibody Syndrome
Sponsor study identifier
observational
60
1 country
1
Study Start
March 2015
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2016
Actual (reported)Study Completion
January 2016
Actual (reported)The purpose of this study is to see if the CoaguChek XS is accurate in measuring International Normalized Ratio (INR) in patients with Antiphospholipid Antibody Syndrome (APL) receiving warfarin therapy.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2016
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 13, 2014
Actual (reported)May 15, 2014
Actual (reported)March 2015
Date type not reportedThis date has not been verified as actual or estimated.
January 2016
Actual (reported)January 2016
Actual (reported)International Normalized Ratio (INR)
Compare INR obtained by CoaguChek XS to INR obtained from venous lab draw. Difference of +/- 0.5 considered significant
Day 1 and Day 60
INR measured by CoaguChek XS in patients with APL at visit 1 and visit 2, in addition to routine measure by standard lab draw
INR measured by standard lab draw at visit 1 and visit 2 for non-APL patients, in addition to routine measurement by CoaguChek XS
CoaguChek XS will be used to measure INR in patients with APL
Patients on warfarin for any indication other than APL will measure INR by venous lab draw
Patients presenting to UF/Shands Hematology Anticoagulation Clinic for a routine office visit with pharmacy.
UF and Shands Health
Gainesville, Florida, 32610, United States
James Taylor, PharmD
University of Florida
60 participants (actual enrollment reported by the registry).
First Submitted
May 13, 2014
First Posted
May 15, 2014
Study Start
March 2015
Date type not reportedThis date has not been verified as actual or estimated.
Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
January 2016
Actual (reported)Study Completion
January 2016
Actual (reported)Last Updated
October 4, 2016
Record last verified: 2016-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: